GSK and Amicus Therapeutics Revise Migalastat Agreement - - BioPharm International

ADVERTISEMENT

GSK and Amicus Therapeutics Revise Migalastat Agreement



Untitled Document

GlaxoSmithKline (GSK) and Amicus Therapeutics have revised their drug-development under which Amicus has obtained global rights to develop and commercialize the investigational pharmacological chaperone migalastat HCl as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Under the terms of the revised agreement:

  • Amicus will have sole rights to the global drug development, regulatory and commercial activities for the next-generation Fabry ERT (migalastat HCl co-formulated with ERT) as well as migalastat HCl monotherapy
  • GSK will be eligible for future regulatory and commercial milestone payments, as well as royalty payments.
  • GSK will further invest $3 million in Amicus through an equity investment in a concurrent private placement in public equity (PIPE) transaction

Source: GlaxoSmithKline

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

USP Awards Analytical Research
August 15, 2014
FDA Warns about Fraudulent Ebola Treatments
August 15, 2014
Guilty Plea to Importing Illegal Cancer Drugs
August 15, 2014
Amgen Recalls Aranesp Prefilled Syringes
August 15, 2014
Report Predicts Generics Production Return to US
August 15, 2014
Author Guidelines

Click here